CN115361947A - 治疗SARS-CoV-2感染的方法 - Google Patents

治疗SARS-CoV-2感染的方法 Download PDF

Info

Publication number
CN115361947A
CN115361947A CN202180027309.8A CN202180027309A CN115361947A CN 115361947 A CN115361947 A CN 115361947A CN 202180027309 A CN202180027309 A CN 202180027309A CN 115361947 A CN115361947 A CN 115361947A
Authority
CN
China
Prior art keywords
dantrolene
administering
subject
acceptable salt
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027309.8A
Other languages
English (en)
Chinese (zh)
Inventor
阿德里安·赫普纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eagle Pharmaceuticals Inc
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of CN115361947A publication Critical patent/CN115361947A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180027309.8A 2020-04-10 2021-04-08 治疗SARS-CoV-2感染的方法 Pending CN115361947A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063008486P 2020-04-10 2020-04-10
US63/008,486 2020-04-10
US202063062599P 2020-08-07 2020-08-07
US63/062,599 2020-08-07
PCT/US2021/026302 WO2021207443A1 (en) 2020-04-10 2021-04-08 Methods of treating sars-cov-2 infections

Publications (1)

Publication Number Publication Date
CN115361947A true CN115361947A (zh) 2022-11-18

Family

ID=75787221

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027309.8A Pending CN115361947A (zh) 2020-04-10 2021-04-08 治疗SARS-CoV-2感染的方法

Country Status (12)

Country Link
US (1) US12605364B2 (https=)
EP (1) EP4132518B1 (https=)
JP (1) JP2023521163A (https=)
KR (1) KR20230002371A (https=)
CN (1) CN115361947A (https=)
AU (1) AU2021253866A1 (https=)
BR (1) BR112022020193A2 (https=)
CA (1) CA3174710A1 (https=)
IL (1) IL296517A (https=)
MX (1) MX2022012705A (https=)
WO (1) WO2021207443A1 (https=)
ZA (1) ZA202210474B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021254415A1 (en) * 2020-04-10 2022-10-20 Eagle Pharmaceuticals, Inc. Methods of treating Severe Acute Respiratory Syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY201417A (en) * 2017-10-20 2024-02-21 Eagle Res Labs Limited Dantrolene prodrugs and methods of their use
US11123328B2 (en) 2017-11-14 2021-09-21 University Health Network Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction
WO2019175761A1 (en) 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions
US12246028B2 (en) * 2018-11-27 2025-03-11 Eagle Research Labs Limited Use of dantrolene and dantrolene prodrugs to treat radiation exposure
AU2021254415A1 (en) * 2020-04-10 2022-10-20 Eagle Pharmaceuticals, Inc. Methods of treating Severe Acute Respiratory Syndrome

Also Published As

Publication number Publication date
KR20230002371A (ko) 2023-01-05
US20230144719A1 (en) 2023-05-11
ZA202210474B (en) 2025-12-17
MX2022012705A (es) 2022-11-07
WO2021207443A1 (en) 2021-10-14
AU2021253866A1 (en) 2022-10-20
JP2023521163A (ja) 2023-05-23
EP4132518A1 (en) 2023-02-15
IL296517A (en) 2022-11-01
US12605364B2 (en) 2026-04-21
EP4132518C0 (en) 2025-08-13
CA3174710A1 (en) 2021-10-14
BR112022020193A2 (pt) 2022-11-22
EP4132518B1 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
Li et al. Therapeutic strategies for critically ill patients with COVID-19
Van Brummelen et al. The potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19–a formulator’s perspective
CN113244212B (zh) 黄芩素在制备预防和/或治疗新型冠状病毒感染疾病的药物中的应用
WO2021155777A1 (zh) 药物组合物在预防和治疗新型冠状病毒肺炎中的应用
EP4132518B1 (en) Dantrolene for use in methods of treating sars-cov-2 infections
US12582633B2 (en) Methods of treating severe acute respiratory syndrome
CN112805027B (zh) 一种抗新冠病毒感染的药物与应用
WO2022143710A1 (zh) 吡咯喹啉醌、其衍生物和/或盐作为抗病毒新药的用途及其药物组合物
US20230181509A1 (en) The use of diffusion enhancing compounds for treatment of viral and bacterial induced respiratory disease
WO2022199049A1 (zh) 乌司他丁在制备治疗新型冠状病毒肺炎药物中的用途
HK40083259A (en) Dantrolene for use in methods of treating sars-cov-2 infections
HK40083259B (en) Dantrolene for use in methods of treating sars-cov-2 infections
WO2021207445A1 (en) Methods of treating coronavirus infections
HK40090314A (zh) 治疗严重急性呼吸综合征的方法
EP4132517A1 (en) Methods of treating viral infections
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
JP2025527908A (ja) 気道感染症を処置するための医薬乾燥粉末組成物および方法
KR20220009314A (ko) 사스-코로나바이러스-2 감염증 예방 또는 치료용 약학 조성물
TW202102224A (zh) 使用經取代之多環吡啶酮衍生物及其前藥於患有流感及嚴重流感病況之個體中治療流感
EA048350B1 (ru) Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви
IL294894A (en) A peptide for the prevention or treatment of covid-19

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination